PODD on Nasdaq
Insulet (United States)
Insulin delivery device company based in Bedford, founded in 20001
In its 2026 annual report the company says: “We also produce pods for Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels.”5 Its shares trade on Nasdaq under the symbol PODD.1
Price unavailable
Last updated Oct 21, 2026.
Overview
2000Founded1
Compare with Globus Medical, West Pharmaceutical Services (United States) or MiniMed Group, Inc., or pick any stock.
- TickerPODD on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersBedford1
- Websitewww.insulet.com
- Incorporated inDE3
- Business address100 Nagog Park, Acton, Ma 017203
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH ® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
71.6%Gross margin6
17.5%Operating margin6
9.1%Net margin6
30.7%Revenue growth, 20256
16.3%Return on equity6
$377.7MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
U.S. Omnipod brought in 71% of the revenue Insulet (United States) broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| U.S. Omnipod | $1.3B | $1.5B | $1.9B |
| International Omnipod | $410.1M | $523.4M | $754.3M |
| Drug Delivery | $36.0M | $38.9M | $34.1M |
Regions
United States brought in 72% of the revenue Insulet (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.3B | $1.5B | $2.0B |
| Outside the United States | $410.1M | $523.4M | $754.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue28¢$768.2M
- Research and development11¢$301.1M
- Selling, general and admin43¢$1.2B
- Other costs5¢$134.3M
- Income tax3¢$92.4M
- Profit9¢$247.1M
Out of $2.7B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending34¢$191.6M
- Share buybacks10¢$59.6M
- Kept or used elsewhere56¢$318.1M
Out of $569.3M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $2.7B | $2.1B | $1.7B |
| Cost of revenue | $768.2M | $625.9M | $537.2M |
| Gross profit | $1.9B | $1.4B | $1.2B |
| Research and development expenses | $301.1M | $219.6M | $205.0M |
| Selling, general and administrative expenses | $1.2B | $917.2M | $734.8M |
| Operating income | $473.8M | $308.9M | $220.1M |
| Interest expense, net of portion capitalized (Note 8) | -$59.4M | -$42.7M | -$36.2M |
| Interest income | $34.7M | $39.5M | $28.6M |
| Loss on extinguishment of debt | -$123.9M | $0 | $0 |
| Other income (expense), net | $14.3M | -$5.5M | $2.2M |
| Income before income taxes | $339.5M | $300.2M | $214.7M |
| Income tax (expense) benefit | -$92.4M | $118.1M | -$8.3M |
| Net income | $247.1M | $418.3M | $206.3M |
| Basic (in dollars per share) | $3.51 | $5.97 | $2.96 |
| Diluted (in dollars per share) | $3.48 | $5.78 | $2.94 |
| Basic (in shares) | 70.3M shares | 70.1M shares | 69.8M shares |
| Diluted (in shares) | 71.9M shares | 73.9M shares | 73.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $716.1M | $953.4M | ||
| Inventories | $452.6M | $430.4M | ||
| Prepaid expenses and other current assets | $228.3M | $142.0M | ||
| Total current assets | $1.9B | $1.9B | ||
| Property, plant and equipment, net | $819.5M | $723.1M | ||
| Other intangible assets, net | $117.1M | $98.5M | ||
| Goodwill | $51.6M | $51.5M | $51.7M | |
| Deferred tax assets | $82.4M | $141.8M | ||
| Other assets (includes $1.0 and $10.1 at fair value) | $205.8M | $181.5M | ||
| Total assets | $3.2B | $3.1B | ||
| Accounts payable | $75.0M | $19.8M | ||
| Current portion of long-term debt | $18.4M | $83.8M | ||
| Total current liabilities | $680.1M | $528.4M | ||
| Long-term debt, net | $930.8M | $1.3B | ||
| Other liabilities | $64.4M | $51.7M | ||
| Total liabilities | $1.7B | $1.9B | ||
| Preferred stock, $.001 par value, 5,000,000 authorized; none issued and outstanding | $0 | $0 | ||
| Common stock, $.001 par value, 100,000,000 authorized; 70,588,192 and 70,390,816 shares issued and outstanding, respectively, at December 31, 2025; and 70,196,031 issued and outstanding, at December 31, 2024 | $100.0K | $100.0K | ||
| Additional paid-in capital | $1.3B | $1.2B | ||
| Accumulated earnings (deficit) | $287.4M | $40.3M | ||
| Accumulated other comprehensive income (loss) | $12.5M | -$13.2M | ||
| Treasury stock, at cost; 197,374 and shares | -$60.4M | $0 | ||
| Deferred compensation | $800.0K | $0 | ||
| Total stockholders equity | $1.5B | $1.2B | $732.7M | $476.4M |
| Total liabilities and stockholders equity | $3.2B | $3.1B | ||
| Other assets, at fair value | $1.0M | $10.1M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, issued (in shares) | 70.6M shares | 70.2M shares | ||
| Common stock, outstanding (in shares) | 70.4M shares | 70.2M shares | ||
| Treasury stock (in shares) | 197.4M shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $716.1M | $953.4M | ||
| Inventories | $452.6M | $430.4M | ||
| Prepaid expenses and other current assets | $228.3M | $142.0M | ||
| Total current assets | $1.9B | $1.9B | ||
| Property, plant and equipment, net | $819.5M | $723.1M | ||
| Other intangible assets, net | $117.1M | $98.5M | ||
| Goodwill | $51.6M | $51.5M | $51.7M | |
| Deferred tax assets | $82.4M | $141.8M | ||
| Other assets (includes $1.0 and $10.1 at fair value) | $205.8M | $181.5M | ||
| Total assets | $3.2B | $3.1B | ||
| Accounts payable | $75.0M | $19.8M | ||
| Current portion of long-term debt | $18.4M | $83.8M | ||
| Total current liabilities | $680.1M | $528.4M | ||
| Long-term debt, net | $930.8M | $1.3B | ||
| Other liabilities | $64.4M | $51.7M | ||
| Total liabilities | $1.7B | $1.9B | ||
| Preferred stock, $.001 par value, 5,000,000 authorized; none issued and outstanding | $0 | $0 | ||
| Common stock, $.001 par value, 100,000,000 authorized; 70,588,192 and 70,390,816 shares issued and outstanding, respectively, at December 31, 2025; and 70,196,031 issued and outstanding, at December 31, 2024 | $100.0K | $100.0K | ||
| Additional paid-in capital | $1.3B | $1.2B | ||
| Accumulated earnings (deficit) | $287.4M | $40.3M | ||
| Accumulated other comprehensive income (loss) | $12.5M | -$13.2M | ||
| Treasury stock, at cost; 197,374 and shares | -$60.4M | $0 | ||
| Deferred compensation | $800.0K | $0 | ||
| Total stockholders equity | $1.5B | $1.2B | $732.7M | $476.4M |
| Total liabilities and stockholders equity | $3.2B | $3.1B | ||
| Other assets, at fair value | $1.0M | $10.1M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 5.0M shares | 5.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, issued (in shares) | 70.6M shares | 70.2M shares | ||
| Common stock, outstanding (in shares) | 70.4M shares | 70.2M shares | ||
| Treasury stock (in shares) | 197.4M shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $247.1M | $418.3M | $206.3M |
| Depreciation and amortization | $90.4M | $80.8M | $72.8M |
| Stock-based compensation expense | $62.7M | $69.3M | $48.4M |
| Deferred income taxes | $62.2M | -$136.9M | $500.0K |
| Non-cash interest expense | $6.2M | $7.3M | $6.7M |
| Loss on extinguishment of debt | $123.9M | $0 | $0 |
| Gain on derivative asset | -$12.5M | $0 | $0 |
| Provisions for credit losses | $5.4M | -$200.0K | $2.3M |
| Loss (gain) on investments | $0 | $3.9M | -$2.6M |
| Other | $7.0M | $4.9M | $2.0M |
| Inventories | -$10.6M | -$32.4M | -$53.6M |
| Prepaid expenses and other assets | -$81.7M | -$21.9M | -$42.1M |
| Accounts payable | $49.2M | $2.2M | -$11.0M |
| Net cash provided by operating activities | $569.3M | $430.2M | $145.7M |
| Capital expenditures | -$191.6M | -$124.9M | -$75.6M |
| Investments in developed software | -$19.2M | -$9.1M | -$8.5M |
| Acquisition of other intangible assets | -$8.6M | $0 | -$25.1M |
| Cash paid for investments | $0 | -$12.2M | -$7.2M |
| Other | -$3.2M | $0 | -$3.0M |
| Net cash used in investing activities | -$222.7M | -$146.2M | -$119.4M |
| Proceeds from issuance of senior unsecured notes, net of issuance costs | $440.7M | $0 | $0 |
| Proceeds from issuance of Term Loan B, net of issuance costs | $15.5M | $130.0M | $0 |
| Repayment of Term Loan B | -$20.5M | -$137.2M | -$5.0M |
| Repayment of equipment financings | -$18.2M | -$19.0M | -$19.8M |
| Repayment of Convertible Senior Notes | -$1.1B | $0 | $0 |
| Financing lease repayments | $0 | -$22.7M | $0 |
| Repayment of mortgage | -$60.9M | -$2.4M | -$2.2M |
| Proceeds from secured borrowing (Note 5) | $49.9M | $45.5M | $0 |
| Repayment of secured borrowing (Note 5) | -$62.4M | -$34.8M | $0 |
| Settlement of capped call options | $164.6M | $0 | $0 |
| Repurchase of common stock | -$59.6M | $0 | $0 |
| Proceeds from exercise of stock options | $19.0M | $8.2M | $16.3M |
| Proceeds from issuance of common stock under employee stock purchase plan | $14.9M | $11.9M | $10.6M |
| Payment of withholding taxes in connection with vesting of restricted stock units | -$25.9M | -$7.6M | -$13.2M |
| Other | $0 | $0 | -$300.0K |
| Net cash used in financing activities | -$595.3M | -$28.0M | -$13.6M |
| Effect of exchange rate changes on cash and cash equivalents | $11.5M | -$6.8M | $1.8M |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -$237.3M | $249.2M | $14.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Insulet (United States) sits at the top of its group. 24 entities, 16 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Insulet (United States)
- FMR LLC Filed SCHEDULE 13G/A on Insulet (United States), latest Aug 6, 2026 (8 filings since Feb 9, 2022)
- Capital Research Global Investors Filed SCHEDULE 13G/A on Insulet (United States), latest May 14, 2026 (7 filings since Feb 11, 2022)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Insulet (United States), latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Insulet (United States), latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- Capital World Investors Filed SC 13G/A on Insulet (United States), latest Feb 9, 2024 (3 filings since Feb 11, 2022)
- Wellington Management Company Filed SC 13G/A on Insulet (United States), latest Feb 8, 2024 (2 filings since Feb 6, 2023)
- BlackRock Filed SC 13G/A on Insulet (United States), latest Jan 25, 2024 (3 filings since Feb 3, 2022)
- Insulet (United States) Bedford
- 3-102-937085 Sociedad de Responsabilidad Limitada Subsidiary · Costa Rica
- Insulet Asia (Singapore) Pte. Ltd. Subsidiary · Singapore
- Insulet Australia Pty Ltd Subsidiary · Australia
- Insulet Austria GmbH Subsidiary · Austria
- Insulet Canada Corporation Subsidiary · Canada
- Insulet Consulting (Shenzhen) Co., Ltd. Subsidiary · China
- Insulet France SAS Subsidiary · France
- Insulet Germany GmbH Subsidiary · Germany
- Insulet Guadalajara, S. de R.L. de C.V. Subsidiary · Mexico
- Insulet International Holdings Ltd. Subsidiary · United Kingdom
- Insulet International Ltd. Subsidiary · United Kingdom
- Insulet MA Securities Corporation Subsidiary · Massachusetts, United States
- Insulet Malaysia Sdn. Bhd. Subsidiary · Malaysia
- Insulet Mexico Investments LLC Subsidiary · Delaware, United States
- Insulet Mexico, S. de R.L. de C.V. Subsidiary · Mexico
- Insulet Netherlands B.V. Subsidiary · Netherlands
- Insulet Netherlands Holdings B.V. Subsidiary · Netherlands
- Insulet Portugal, Unipessoal Lda Subsidiary · Portugal
- Insulet Realty Holdings LLC Subsidiary · Delaware, United States
- Insulet Singapore Private Limited Subsidiary · Singapore
- Insulet Spain S.L. Subsidiary · Spain
- Insulet Switzerland GmbH Subsidiary · Switzerland
- Sub-Q Solutions, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Insulet (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $205.1M6 Dec 31, 2025 | $167.0M6 Dec 31, 2024 | +22.8% |
| Finance-lease assets | $010 Dec 31, 2024 | $37.8M10 Dec 31, 2023 | −100.0% |
| Operating-lease assets (leased space) | $43.7M6 Dec 31, 2025 | $36.7M6 Dec 31, 2024 | +19.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Debt securities available for sale | $06 Dec 31, 2025 | $4.7M6 Dec 31, 2024 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $51.6M6 Dec 31, 2025 | $51.5M6 Dec 31, 2024 | +0.2% |
| Finite-lived intangibles, gross | $183.8M6 Dec 31, 2025 | $159.1M6 Dec 31, 2024 | +15.5% |
| Accumulated amortization | $66.7M6 Dec 31, 2025 | $60.6M6 Dec 31, 2024 | +10.1% |
| Finite-lived intangibles, net | $117.1M6 Dec 31, 2025 | $98.5M6 Dec 31, 2024 | +18.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $452.6M6 Dec 31, 2025 | $430.4M6 Dec 31, 2024 | +5.2% |
| Raw materials | $194.1M6 Dec 31, 2025 | $156.7M6 Dec 31, 2024 | +23.9% |
| Work in process | $64.6M6 Dec 31, 2025 | $81.2M6 Dec 31, 2024 | −20.4% |
| Finished goods | $193.9M6 Dec 31, 2025 | $192.5M6 Dec 31, 2024 | +0.7% |
Properties, in its own words
We own a 350,000 square foot facility in Acton, MA, which houses both our headquarters and our U.S. manufacturing. We also own a 400,000 square foot facility in Malaysia, which houses manufacturing and office space. As of December 31, 2025, we leased 12 facilities in 7 countries consisting of approximately 289,000 square feet of office, research and development, and warehousing space and other related facilities, primarily in North America and Europe. Additional information regarding our leases is provided in Note 12 to the consolidated financial statements included in Item 8 of this Form 10-K.
Item 2 of the 10-K filed Feb 18, 2026.5
Leadership
Who has led Insulet (United States), and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
20052010201520202025
- Chief executive officerAshley McEvoy May 2, 2025 to now14
- Chief executive officerJames Hollingshead Jun 2, 2022 to May 2, 202515
- Chief executive officerShacey Petrovic Jan 3, 2019 to Apr 5, 202216
- PresidentAshley McEvoy May 2, 2025 to now14
- PresidentJames Hollingshead Jun 2, 2022 to May 2, 202515
- PresidentShacey Petrovic Feb 25, 2016 to Apr 5, 202217
- PresidentDaniel J. Levangie Feb 11, 2015 to Apr 5, 201618
- Chief financial officerFlavia Pease Oct 2, 2025 to now19
- Chief financial officerLauren Budden Feb 29, 2024 to Feb 29, 202420
- Chief financial officerAna Maria Chadwick Apr 25, 2024 to Oct 2, 202521
- Chief financial officerWayde D. McMillan Feb 26, 2019 to Jul 6, 202322
- Chief financial officerMichael L. Levitz May 4, 2015 to Feb 28, 201923
- Chief financial officerAllison Dorval Nov 17, 2014 to Apr 3, 201524
- Chief financial officerBrian K. Roberts Mar 9, 2009 to Apr 3, 201425
- Chief financial officerCarsten Boess May 14, 2007 to Mar 2, 200926
- Chief operating officerEric Benjamin Feb 17, 2026 to now27
- Chief operating officerCharles Alpuche Feb 28, 2019 to Jun 7, 202228
- Chief operating officerShacey Petrovic Feb 10, 2017 to Dec 10, 201829
- Chief operating officerCharles T. Liamos Jan 11, 2011 to Jan 3, 201430
- Chief operating officerLuis Malave May 14, 2007 to Mar 3, 201031
Board members and other officers (60)
- EVP and CCOMichael Panos Apr 2, 2026 to now32
- SVP, Reg, Quality & ComplianceLaetitia Cousin Apr 3, 2023 to now33
- SVP, Global OperationsPrem Singh Apr 3, 2023 to now34
- SVP, Chief HR OfficerDan Manea May 28, 2020 to now35
- SVP, Secretary and GCJohn W. Kapples Mar 22, 2019 to Apr 2, 202136
- VP, CAO and ControllerLauren Budden May 1, 2019 to now37
- SVP, R&D, New Prod Dev. & CommEric Benjamin Feb 16, 2018 to now38
- SVP and CCOBret Christensen May 31, 2017 to Mar 1, 202339
- SVP, Global ManufacturingCharles Alpuche Feb 5, 2016 to Mar 15, 202340
- SVP, Secretary and GCDavid Colleran Feb 26, 2016 to Apr 4, 201941
- SVP, Quality and RegulatoryMichael P. Spears Feb 26, 2016 to Mar 13, 202342
- SVP, Advanced TechnologyAiman Abdel-Malek Mar 30, 2016 to Apr 1, 201943
- EVP & President, Drug DeliveryDaniel J. Levangie May 2, 2016 to May 2, 201644
- CCOShacey Petrovic Feb 11, 2015 to Mar 16, 202345
- VP, Global Regulatory, CA, QATracey Haas Wielinski Feb 28, 2014 to Mar 7, 201446
- Vice President, HRKathleen Hayes Sep 30, 2014 to Sep 30, 201447
- EVP Human ResourcesBradley A. Thomas Nov 17, 2014 to Apr 2, 201848
- Vice President, InternationalCarsten Boess Mar 3, 2010 to Apr 27, 201149
- VP of Human ResourcesDavid A. Howe Jan 26, 2009 to Mar 2, 200950
- Chief Commercial OfficerPeter Devlin Aug 18, 2009 to Jun 10, 201451
- Vice President of Asian OperatJason Ng Mar 14, 2008 to Mar 2, 200952
- Chief Human Resources OfficerAndrew Suchoff Mar 31, 2008 to Mar 31, 200853
- V.P. of Business DevelopmentWilliam D. Arthur Iii. Sep 4, 2008 to Mar 2, 200954
- Vice President of ResearchJohn Garibotto May 14, 2007 to Mar 2, 200955
- Vice President ManufacturingKevin Schmid May 14, 2007 to Mar 2, 200956
- Vice President of QualityRuthann Depietro May 14, 2007 to Sep 6, 201257
- Vice President of SalesShawna Gvazdauskas May 14, 2007 to Mar 2, 200958
- Vice President of FinanceLars Boesgaard Jun 25, 2007 to Mar 2, 200959
- Vice President of CustomerStephen Bubrick Aug 10, 2007 to Aug 10, 200760
- Board memberJay Mazelsky Jul 2, 2026 to now61
- Board memberAshley McEvoy May 2, 2025 to now14
- Board memberRobert Luther Huffines Nov 3, 2025 to now62
- Board memberFlavia Pease Jan 22, 2024 to now63
- Board memberTimothy C. Stonesifer Jan 22, 2024 to now64
- Board memberElizabeth H. Weatherman Feb 7, 2022 to now65
- Board memberLuciana Borio Oct 18, 2021 to now66
- Board memberWayne A.I. Frederick Oct 20, 2020 to now67
- Board memberShacey Petrovic Jan 3, 2019 to Feb 29, 202416
- Board memberCorinne H. Lyle Jan 29, 2019 to May 24, 202368
- Board memberJames Hollingshead Aug 1, 2019 to now69
- Board memberJames Mullen Aug 11, 2017 to May 18, 201870
- Board memberMichael R. Minogue Aug 11, 2017 to now71
- Board memberJessica Hopfield Jul 29, 2015 to now72
- Board memberTimothy J. Scannell Aug 19, 2014 to now73
- Board memberW. Mark Lortz Aug 1, 2012 to Jun 5, 201374
- Board memberDaniel J. Levangie Oct 25, 2011 to Jun 13, 201475
- Board memberJoseph S. Zakrzewski May 12, 2008 to May 18, 201776
- Board memberRegina O. Sommer May 12, 2008 to May 18, 201777
- Board memberSally Crawford Oct 23, 2008 to Jun 7, 202178
- Board memberCharles T. Liamos May 14, 2007 to Apr 3, 201579
- Board memberDe Bord Alison Peyromaure May 14, 2007 to May 12, 200880
- Board memberGary Eichhorn May 14, 2007 to Apr 21, 200981
- Board memberGordon E. Nye May 14, 2007 to Feb 7, 200882
- Board memberJonathan Silverstein May 14, 2007 to May 18, 200783
- Board memberRoss A. Jaffe Md. May 14, 2007 to Feb 22, 201284
- Board memberSamuel D. Isaly May 14, 2007 to May 14, 200785
- Board memberSteven Sobieski May 14, 2007 to May 18, 201586
- General counselJohn W. Kapples Feb 11, 2022 to now87
- General counselDavid Colleran Jul 20, 2015 to Jul 20, 201588
- General counselR. Anthony Diehl May 14, 2007 to May 13, 201589
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 3-102-937085 Sociedad de Responsabilidad Limitada Costa Rica4
- Insulet Asia (Singapore) Pte. Ltd. Singapore4
- Insulet Australia Pty Ltd Australia4
- Insulet Austria GmbH Austria4
- Insulet Canada Corporation Canada4
- Insulet Consulting (Shenzhen) Co., Ltd. China4
- Insulet France SAS France4
- Insulet Germany GmbH Germany4
- Insulet Guadalajara, S. de R.L. de C.V. Mexico4
- Insulet International Holdings Ltd. United Kingdom4
- Insulet International Ltd. United Kingdom4
- Insulet MA Securities Corporation Massachusetts4
- Insulet Malaysia Sdn. Bhd. Malaysia4
- Insulet Mexico Investments LLC Delaware4
- Insulet Mexico, S. de R.L. de C.V. Mexico4
- Insulet Netherlands B.V. Netherlands4
- Insulet Netherlands Holdings B.V. Netherlands4
- Insulet Portugal, Unipessoal Lda Portugal4
- Insulet Realty Holdings LLC Delaware4
- Insulet Singapore Private Limited Singapore4
- Insulet Spain S.L. Spain4
- Insulet Switzerland GmbH Switzerland4
- Sub-Q Solutions, Inc. Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Sep 21, 20268-K Entered a material agreement; New debt or obligation90
- Sep 16, 20268-K Executive or director change91
- Sep 10, 20268-K Executive or director change92
- Aug 5, 20268-K Results of operations93
- Jun 25, 20268-K Executive or director change; Regulation FD disclosure94
- May 26, 20268-K Regulation FD disclosure95
- May 21, 20268-K Bylaws or fiscal year changed; Shareholder vote96
- May 6, 20268-K Results of operations97
- Apr 29, 20268-K Regulation FD disclosure98
- Mar 12, 20268-K Regulation FD disclosure99
- Mar 4, 20268-K Executive or director change100
- Feb 24, 20268-K Change of auditor101
- May 2, 2025New chief executive Ashley McEvoy becomes CEO14
- Jun 2, 2022New chief executive James Hollingshead becomes CEO15
- Jan 3, 2019New chief executive Shacey Petrovic becomes CEO16
- 2000Founded Founded1
Calendar
Coming up
- Nov 4, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.24 a share, on Nov 6, 2025.102
When it reported results
- Aug 5, 2026Reported quarterly or annual results93
- May 6, 2026Reported quarterly or annual results97
- Feb 18, 2026Reported quarterly or annual results103
- Nov 6, 2025Reported quarterly or annual results104
- Aug 7, 2025Reported quarterly or annual results105
- May 8, 2025Reported quarterly or annual results106
- Feb 20, 2025Reported quarterly or annual results107
- Nov 7, 2024Reported quarterly or annual results108
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
490 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 78 major events, 292 insider forms, 30 large holders, 70 other. The latest 20:
- Oct 5, 20264 PRIMARY DOCUMENT EDGAR
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Sep 21, 20268-K EDGAR
- Sep 16, 20268-K EDGAR
- Sep 10, 20268-K EDGAR
- Aug 24, 20264 PRIMARY DOCUMENT EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Aug 4, 20264 PRIMARY DOCUMENT EDGAR
- Jul 7, 20264/A PRIMARY DOCUMENT EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 20263 PRIMARY DOCUMENT EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20268-K EDGAR
- Jun 4, 20264 PRIMARY DOCUMENT EDGAR
- Jun 4, 20264 PRIMARY DOCUMENT EDGAR
- Jun 3, 2026144 EDGAR
- Jun 3, 20264 PRIMARY DOCUMENT EDGAR
The 490 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
65 open-market trades by officers, directors and large owners since October 2021: 10 buys and 55 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | McEvoy AshleyPresident and CEO | Buy | 1,100 | $147.47 | $162.2K | Form 4 |
| Jun 3, 2026 | STONESIFER TIMOTHY C.Director | Buy | 2,790 | $143.51 | $400.4K | Form 4 |
| Jun 3, 2026 | BORIO LUCIANADirector | Sale | 418 | $143.27 | $59.9K | Form 4 |
| Jun 3, 2026 | WEATHERMAN ELIZABETH HDirector | Buy | 3,450 | $144.20 | $497.5K | Form 4 |
| Feb 25, 2026 | MINOGUE MICHAEL RDirector | Buy | 2,030 | $246.23 | $499.8K | Form 4 |
| Feb 20, 2026 | McEvoy AshleyPresident and CEO | Buy | 4,300 | $239.35 | $1.0M | Form 4 |
| Dec 15, 2025 | Frederick Wayne A.I.Director | Sale | 1,851 | $293.09 | $542.5K | Form 4 |
| Dec 5, 2025 | STONESIFER TIMOTHY C.Director | Buy | 962 | $311.73 | $299.9K | Form 4 |
| Sep 8, 2025 | Singh PremSVP, Global Operations | Sale | 687 | $347.49 | $238.7K | Form 4 |
| Sep 8, 2025 | Cousin LaetitiaSVP, Reg, Quality & Compliance | Sale | 797 | $348.81 | $278.0K | Form 4 |
| Aug 21, 2025 | Benjamin EricEVP and COO | Sale | 4,263 | $332.23 | $1.4M | Form 4 |
| Aug 7, 2025 | Singh PremSVP, Global Operations | Sale | 1,343 | $320.00 | $429.8K | Form 4 |
| Jun 13, 2025 | Singh PremSVP, Global Operations | Sale | 2,327 | $300.05 | $698.2K | Form 4 |
| Jun 13, 2025 | Manea DanSVP, Chief HR Officer | Sale | 1,300 | $300.05 | $390.1K | Form 4 |
| Jun 9, 2025 | BORIO LUCIANADirector | Sale | 481 | $305.73 | $147.1K | Form 4 |
| May 14, 2025 | Kapples John W.SVP and General Counsel | Sale | 5,278 | $318.47 | $1.7M | Form 4 |
| May 13, 2025 | Hopfield JessicaDirector | Sale | 5,235 | $317.54 | $1.7M | Form 4 |
| May 13, 2025 | Benjamin EricEVP and COO | Sale | 3,001 | $320.00 | $960.3K | Form 4 |
| Mar 25, 2025 | Frederick Wayne A.I.Director | Sale | 1,825 | $275.00 | $501.9K | Form 4 |
| Jan 21, 2025 | Benjamin EricEVP and COO | Sale | 12,394 | $280.00 | $3.5M | Form 4 |
All 65 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G/A, 8 filings Feb 9, 2022 to Aug 6, 2026109
- Capital Research Global InvestorsSCHEDULE 13G/A, 7 filings Feb 11, 2022 to May 14, 2026110
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 2026111
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 2026112
- Capital World InvestorsSC 13G/A, 3 filings Feb 11, 2022 to Feb 9, 2024113
- Wellington Management CompanySC 13G/A, 2 filings Feb 6, 2023 to Feb 8, 2024114
- BlackRockSC 13G/A, 3 filings Feb 3, 2022 to Jan 25, 2024115
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Ashley McEvoyPresident and Chief Executive Officer | 55 | $729.8K | $18.9M116 |
| 2025 | James HollingsheadFormer President and Chief Executive Officer | $357.5K | $13.2M116 | |
| 2025 | Flavia PeaseExecutive Vice President, Chief Financial Officer | $148.5K | $5.2M116 | |
| 2025 | Eric BenjaminExecutive Vice President, Chief Operating Officer | $596.3K | $4.5M116 | |
| 2025 | Ana ChadwickFormer Executive Vice President, Former Chief Financial Officer | $653.0K | $4.4M116 | |
| 2025 | Mark FieldFormer Senior Vice President, Chief Technology Officer | $118.3K | $3.2M116 | |
| 2025 | John KapplesSenior Vice President, General Counsel | $526.6K | $3.1M116 | |
| 2025 | Prem SinghSenior Vice President, Global Operations | $442.7K | $2.5M116 | |
| 2024 | James HollingsheadFormer President and Chief Executive Officer | $930.8K | $13.3M116 | |
| 2024 | Ana ChadwickFormer Executive Vice President, Former Chief Financial Officer | $411.9K | $4.6M116 | |
| 2024 | Eric BenjaminExecutive Vice President, Chief Operating Officer | $540.4K | $4.1M116 | |
| 2024 | Mark FieldFormer Senior Vice President, Chief Technology Officer | $466.2K | $3.5M116 | |
| 2024 | John KapplesSenior Vice President, General Counsel | $501.0K | $2.9M116 | |
| 2023 | James HollingsheadFormer President and Chief Executive Officer | $842.3K | $12.4M116 | |
| 2023 | Eric BenjaminExecutive Vice President, Chief Operating Officer | $469.2K | $3.1M116 | |
| 2023 | John KapplesSenior Vice President, General Counsel | $461.1K | $2.5M116 | |
| 2023 | Mark FieldFormer Senior Vice President, Chief Technology Officer | $426.5K | $2.4M116 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 6,690,192 | $1.0B | 0.0% | +314,249 |
| Vanguard Capital Management LLC | 4,525,333 | $689.0M | 0.0% | −53,941 |
| State Street Corp | 3,197,555 | $486.8M | 0.0% | +155,101 |
| Vanguard Portfolio Management LLC | 3,075,932 | $468.3M | 0.0% | −374,055 |
| Aqr Capital Management LLC | 2,455,135 | $373.8M | 0.1% | +856,411 |
| Baillie Gifford & Co | 2,042,313 | $310.9M | 0.3% | +12,821 |
| Geode Capital Management, LLC | 2,003,861 | $304.0M | 0.0% | −21,837 |
| Two Sigma Investments, LP | 1,903,734 | $289.8M | 0.2% | +1,141,385 |
| Invesco Ltd. | 1,694,651 | $258.0M | 0.0% | +598,114 |
| Morgan Stanley | 1,479,050 | $225.2M | 0.0% | +333,119 |
| Arrowstreet Capital, Limited Partnership | 1,471,069 | $224.0M | 0.1% | +241,141 |
| Clearbridge Investments, LLC | 1,319,381 | $200.9M | 0.2% | −1,645 |
| Soleus Capital Management, L.P. | 1,049,000 | $159.7M | 5.5% | +486,500 |
| Norges Bank | 1,047,986 | $159.6M | 0.0% | New |
| Jupiter Asset Management Ltd | 1,026,691 | $156.3M | 0.8% | +316,789 |
| Fmr LLC | 964,297 | $146.8M | 0.0% | −3,010,415 |
| Millennium Management LLC | 865,387 | $131.8M | 0.1% | +566,795 |
| FIL Ltd | 840,026 | $127.9M | 0.1% | −171,979 |
| Goldman Sachs Group Inc | 818,265 | $124.6M | 0.0% | −45,651 |
| Citadel Advisors LLC | 796,746 | $121.3M | 0.1% | +643,307 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 773,361 | $117.7M | 0.0% | −21,986 |
| Federated Hermes, Inc. | 702,194 | $106.9M | 0.2% | −11,698 |
| Vestal Point Capital, LP | 670,000 | $102.0M | 2.4% | +619,399 |
| Qube Research & Technologies Ltd | 663,968 | $101.1M | 0.1% | +22,292 |
| Northern Trust Corp | 649,908 | $98.9M | 0.0% | −43,909 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
11 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Sep 18, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +2.6% | Report |
| Aug 18, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −6.8% | Report |
| May 7, 2026 | Tina SmithDemocratic, Senate | Sale | $100,001 - $250,000 | +19.0% | Report |
| Apr 29, 2026 | Tina SmithDemocratic, Senate | Partial sale | $100,001 - $250,000 | +21.7% | Report |
| Apr 4, 2024 | Tina SmithDemocratic, Senate | Partial sale | $50,001 - $100,000 | +65.4% | Report |
| Jan 4, 2024 | Markwayne Mullin, Senate | Sale | $1,001 - $15,000 | +95.7% | Report |
| Dec 22, 2023 | Markwayne Mullin, Senate | Partial sale | $1,001 - $15,000 | +98.8% | Report |
| Jul 12, 2023 | Daniel S. GoldmanDemocratic, House | Sale | $1,001 - $15,000 | +124.4% | Report |
| Apr 10, 2023 | Daniel S. GoldmanDemocratic, House | Buy | $1,001 - $15,000 | −144.4% | Report |
| Jan 3, 2023 | Markwayne Mullin, Senate | Buy | $1,001 - $15,000 | −154.2% | Report |
| Mar 17, 2020 | Tina SmithDemocratic, Senate | Partial sale | $250,001 - $500,000 | +198.6% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Insulet (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARINSULET CORP2
- CIK0001145197
- Employer ID (EIN)04-35238915
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 312
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address100 Nagog Park, Acton, MA 017202
- Phone978-600-70002
- Shares outstanding69,354,199 as of Jul 29, 202612
- Public float$22.1B as of Jun 30, 20255
- AuditorGRANT THORNTON LLP, Boston, Massachusetts PCAOB ID 248; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceSep 19, 20022
- Filings1,748 in all: 4 (953), 8-K (238), SC 13G/A (105), 3 (80), 10-Q (59), 144 (48), SC 13G (31), 10-K (19)2
All 42 form types
DEF 14A (19), UPLOAD (19), CORRESP (15), 4/A (13), DEFA14A (13), SD (13), CT ORDER (12), 10-Q/A (11), S-8 (11), SCHEDULE 13G/A (8), 424B5 (7), ARS (7), 3/A (6), FWP (6), REGDEX (6), 8-K/A (5), EFFECT (5), S-1/A (5), 424B3 (4), S-3ASR (4), 10-K/A (3), 424B4 (3), S-3 (3), SC 13D (3), 5 (2), 8-A12B (2), 8-A12B/A (2), S-1 (2), 424A (1), 424B2 (1), CERTNAS (1), NT 10-Q (1), S-1MEF (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Feb 18, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 6, 2026
Latest 8-K (8-K) Sep 21, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 Par Value Per Share | PODD | The NASDAQ Stock Market, LLC |
From the cover page of the 10-K filed Feb 18, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Insulet (United States) names in Item 1A of its 10-K filed Feb 18, 2026: 36 risks under these headings, as written.5
- Risks Related to Our Business
- We currently rely on sales of our Omnipod product platform to generate most of our revenue.
- Our ability to grow our revenue depends in part on our retaining a high percentage of our customers.
- If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations.
- Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations.
- If we fail to expand our relationships with intermediaries, our ability to grow our business may be materially and adversely affected.
- Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success.
- Risks Related to Competition and Product Development
- Our failure to compete effectively would negatively impact our revenue and results of operations.
- Our new product development initiatives may prove to be ineffective or not commercially successful.
- Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable.
- Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition, and cash flows.
The other 26 risks
- Risks Related to our Intellectual Property
- We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause us to incur additional costs.
- Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs.
- Risks Related to Economic Conditions and Operating Internationally
- The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely affect our business and prospects.
- The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operations.
- Expansion of U.S. tariffs could have a material adverse effect on our financial results.
- Risks Related to Reliance on Third Parties and Business Continuity
- We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products.
- Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our products.
- We are dependent upon third-party suppliers, making us vulnerable to supply constraints and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all.
- Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines or issues with our third-party contract manufacturer, which could harm our business.
- If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or commercialize our products.
- Risks Related to Government Regulation and Product Liability
- Healthcare reform laws could adversely affect our revenue and financial condition.
- We are subject to extensive government regulation, which could restrict the sales and marketing of our products, cause us to incur significant costs, and impact our profitability and competitiveness.
- If we or our contract manufacturer fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer.
- Malfunction of our products could lead to recalls, safety alerts, or litigation and result in substantial costs and reputational damage.
- We may be subject to enforcement action if we engage in improper marketing or promotion of our products.
- If we fail to comply with fraud and abuse and other healthcare regulations, including those relating to Medicare and Medicaid, we could be subject to substantial penalties and/or be excluded from participation in government programs.
- Failure to comply with the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws could materially adversely affect our business and result in civil and/or criminal sanctions.
- Risks Related to Information Technology (“IT”), Privacy and Security
- We are subject to complex and evolving laws and regulations regarding privacy, data protection, and artificial intelligence (“AI”), many of which are subject to change and uncertain interpretation, which could result in legal claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement.
- We rely on the proper function, availability, and security of our products and IT systems; a successful cyber-attack or other breach or disruption of our products or these systems could have a material adverse effect on our business and results of operations.
- Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier, or Company information could result in substantial costs and/or subject us to litigation, enforcement actions, and reputational damage.
- Risks Related to Debt
- Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate or grow our business.
- We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all.
- General Risks
- Our success depends on our ability to attract, motivate, and retain key personnel.
- Acquisitions or investments in new businesses, products, or technologies could disrupt our business.
- The price of our common stock may be volatile.
- Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results.
Legal proceedings
The information required by this Item is provided under “Legal Proceedings” in Note 16 to the consolidated financial statements included in Item 8 of this Form 10-K and is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.5
Links
- Websitewww.insulet.com1
- LinkedInwww.linkedin.com/company/insulet-corporation1
- WikidataQ104480795
- SEC EDGARCIK 1145197
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARShacey Petrovic, President
- 18SEC EDGARDaniel J. Levangie, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARLuis Malave, Chief operating officer
- 32SEC EDGARMichael Panos, EVP and CCO
- 33
- 34SEC EDGARPrem Singh, SVP, Global Operations
- 35SEC EDGARDan Manea, SVP, Chief HR Officer
- 36
- 37
- 38
- 39SEC EDGARBret Christensen, SVP and CCO
- 40
- 41
- 42
- 43
- 44
- 45SEC EDGARShacey Petrovic, CCO
- 46
- 47SEC EDGARKathleen Hayes, Vice President, HR
- 48
- 49
- 50SEC EDGARDavid A. Howe, VP of Human Resources
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61SEC EDGARJay Mazelsky, Board member
- 62SEC EDGARRobert Luther Huffines, Board member
- 63SEC EDGARFlavia Pease, Board member
- 64SEC EDGARTimothy C. Stonesifer, Board member
- 65
- 66SEC EDGARLuciana Borio, Board member
- 67SEC EDGARWayne A.I. Frederick, Board member
- 68SEC EDGARCorinne H. Lyle, Board member
- 69SEC EDGARJames Hollingshead, Board member
- 70SEC EDGARJames Mullen, Board member
- 71SEC EDGARMichael R. Minogue, Board member
- 72SEC EDGARJessica Hopfield, Board member
- 73SEC EDGARTimothy J. Scannell, Board member
- 74SEC EDGARW. Mark Lortz, Board member
- 75SEC EDGARDaniel J. Levangie, Board member
- 76SEC EDGARJoseph S. Zakrzewski, Board member
- 77SEC EDGARRegina O. Sommer, Board member
- 78SEC EDGARSally Crawford, Board member
- 79SEC EDGARCharles T. Liamos, Board member
- 80
- 81SEC EDGARGary Eichhorn, Board member
- 82SEC EDGARGordon E. Nye, Board member
- 83SEC EDGARJonathan Silverstein, Board member
- 84SEC EDGARRoss A. Jaffe Md., Board member
- 85SEC EDGARSamuel D. Isaly, Board member
- 86SEC EDGARSteven Sobieski, Board member
- 87SEC EDGARJohn W. Kapples, General counsel
- 88SEC EDGARDavid Colleran, General counsel
- 89SEC EDGARR. Anthony Diehl, General counsel
- 90
- 91SEC EDGARExecutive or director change
- 92SEC EDGARExecutive or director change
- 93SEC EDGARResults of operations
- 94
- 95SEC EDGARRegulation FD disclosure
- 96
- 97SEC EDGARResults of operations
- 98SEC EDGARRegulation FD disclosure
- 99SEC EDGARRegulation FD disclosure
- 100SEC EDGARExecutive or director change
- 101SEC EDGARChange of auditor
- 102NasdaqNasdaq calendar
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116